(ARGX) argenx - Ratings and Ratios

argenx SE, a commercial-stage biopharmaceutical company, specializes in developing therapies for autoimmune diseases. Its lead products, VYGART and VYGART HYTRULO, are approved for generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). The companys pipeline includes efgartigimod, targeting multiple autoimmune conditions such as seronegative and ocular gMG, thyroid eye diseases, and lupus nephropathy. Other candidates like empasiprubart and ARGX-119 address rare neuromuscular disorders, including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). The company also develops ARGX-112, ARGX-114, and ARGX-115, focusing on Galectin-10 and IL-6 pathways. argenx collaborates with multiple industry and academic partners, including AbbVie, LEO Pharma, and Genmab, to advance its research and development efforts.

Founded in 2008 and headquartered in Amsterdam, the company has built a diverse portfolio targeting autoimmune and rare diseases. Its strategic collaborations span biotech, pharmaceutical, and academic institutions, enhancing its R&D capabilities. The companys focus on novel mechanisms, such as targeting FcRn and IL-6, positions it as a key player in the autoimmune disease space. With a strong emphasis on innovation and partnerships, argenx continues to expand its pipeline and commercial footprint globally.